,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['tnbc', 'breast']
destiny breast -04. standing ovation: 6 mo increase in os in hr pos her-2 low disease and 10 month(!!!!) improvement in os in patients with tnbc her-2 low. #asco22 
Breast oncologist at UMiami passionate about teaming with my patients for best outcomes. #bcsm #sexualhealth #survivorship @sylvestercancer Tweets my own